2.1.1.320: type II protein arginine methyltransferase

This is an abbreviated version!
For detailed information about type II protein arginine methyltransferase, go to the full flat file.

Reaction

2 S-adenosyl-L-methionine +

Synonyms

At4g31120, EC 2.1.1.124, EC 2.1.1.125, EC 2.1.1.126, EC 2.1.1.23, Hsl7, Jak-binding protein 1, Janus kinase-binding protein 1, JBP1, PRMT-5, PRMT-9, PRMT15, PRMT5, PRMT7, PRMT9, protein arginine methyltransferase 5, Skb1

ECTree

     2 Transferases

         2.1 Transferring one-carbon groups

             2.1.1 Methyltransferases

                2.1.1.320 type II protein arginine methyltransferase

Advanced search results

Do not include text mining results

Include results (more...)

Include results (more...)

Results	in table
1	Activating Compound
5693	AA Sequence
4	Application
4	Cloned(Commentary)
5	Crystallization (Commentary)
1867	Disease/ Diagnostics
6	Expression
38	General Information
58	IC50 Value
59	Inhibitors
4	KM Value [mM]
19	Localization
6	Molecular Weight [Da]
15	Natural Substrates/ Products (Substrates)
48	Organism
58	PDB ID
4	Protein Variants
1	Purification (Commentary)
3	Reaction
48	Reference
54	Source Tissue
66	Substrates and Products (Substrate)
4	Subunits
53	Synonyms
1	Systematic Name

Application

print visible entries

print all entries

Go back to the abbreviated version
of the Enzyme Summary Page.

Application on EC 2.1.1.320 - type II protein arginine methyltransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.

top print hide show all columns Go to Application Search

Please wait a moment until the data is sorted. This message will disappear when the data is sorted.

APPLICATION

ORGANISM

UNIPROT

COMMENTARY

LITERATURE

medicine

4 entries

medicine

Homo sapiens

O14744

abundant expression of isoform PRMT5 and its symmetric methylation mark H4R3 in lung carcinoma but not in non-neoplastic human pulmonary alveolar and bronchial epithelial cell lines. More than two thirds of lung tumors express PRMT5. High levels of cytoplasmic PRMT5 are detected in 20.5% of non-small cell lung carcinomas and in 16.5% of pulmonary neuroendocrine tumors. High levels of nuclear PRMT5 are detected in 38.0% of non-small cell lung carcinomas and 24.0% of pulmonary neuroendocrine tumors. Cytoplasmic PRMT5 is associated with high grade in both non-small cell lung carcinomas and pulmonary pulmonary neuroendocrine tumors, while nuclear PRMT5 is more frequent in carcinoid tumors

733704

medicine

Caenorhabditis elegans

P46580

knockdown of isoform PRMT5 results in more paralysis in a Caenorhabditis elegans model of Alzheimer's disease

734525

medicine

Homo sapiens

O14744

PRMT5 localizes in the nucleus in benign prostate epithelium, whereas it localizes in the cytoplasm in prostate premalignant and cancer tissues

735066

medicine

Homo sapiens

O14744

PRMT1 and PRMT5 have opposing effects on chemotherapeutic agent-mediated apoptosis in lung cancer cells. The identification of PRMT5 and PRMT1 as CFLARL regulators involved in cellular apoptosis may help in developing new strategies to increase the sensitivity of cancer cells to chemotherapy, which may eventually benefit lung cancer treatments

757337